JP2023540023A5 - - Google Patents

Info

Publication number
JP2023540023A5
JP2023540023A5 JP2023513273A JP2023513273A JP2023540023A5 JP 2023540023 A5 JP2023540023 A5 JP 2023540023A5 JP 2023513273 A JP2023513273 A JP 2023513273A JP 2023513273 A JP2023513273 A JP 2023513273A JP 2023540023 A5 JP2023540023 A5 JP 2023540023A5
Authority
JP
Japan
Prior art keywords
nucleic acid
cells
car
genetically modified
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023513273A
Other languages
English (en)
Japanese (ja)
Other versions
JP7849891B2 (ja
JP2023540023A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/073363 external-priority patent/WO2022043312A1/en
Publication of JP2023540023A publication Critical patent/JP2023540023A/ja
Publication of JP2023540023A5 publication Critical patent/JP2023540023A5/ja
Application granted granted Critical
Publication of JP7849891B2 publication Critical patent/JP7849891B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023513273A 2020-08-24 2021-08-24 Ceaを認識するキメラ抗原受容体(car)発現細胞 Active JP7849891B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20192398 2020-08-24
EP20192398.4 2020-08-24
EP20205693.3 2020-11-04
EP20205693 2020-11-04
PCT/EP2021/073363 WO2022043312A1 (en) 2020-08-24 2021-08-24 Chimeric antigen receptor (car)-expressing cells recognizing cea

Publications (3)

Publication Number Publication Date
JP2023540023A JP2023540023A (ja) 2023-09-21
JP2023540023A5 true JP2023540023A5 (cg-RX-API-DMAC7.html) 2023-12-18
JP7849891B2 JP7849891B2 (ja) 2026-04-22

Family

ID=77693502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513273A Active JP7849891B2 (ja) 2020-08-24 2021-08-24 Ceaを認識するキメラ抗原受容体(car)発現細胞

Country Status (5)

Country Link
US (1) US20230321242A1 (cg-RX-API-DMAC7.html)
EP (1) EP4199958A1 (cg-RX-API-DMAC7.html)
JP (1) JP7849891B2 (cg-RX-API-DMAC7.html)
AU (1) AU2021334950A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022043312A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116814664B (zh) * 2023-08-25 2023-12-12 中国医学科学院肿瘤医院 一种扩展肿瘤识别表位的cea嵌合抗原受体t细胞的制备与应用
WO2025176860A1 (en) 2024-02-23 2025-08-28 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Dual chimeric antigen receptor construct targeting cea and epcam

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
DK0973928T3 (da) 1997-03-11 2010-08-09 Univ Minnesota DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
AU751647B2 (en) 1998-05-26 2002-08-22 Innogenetics N.V. Method for expanding primate B cells selectively in immunocompromised mice and producing large numbers of antigen-specific B lymphocytes for the production of primate monoclonal antibodies
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US9228180B2 (en) 2007-07-04 2016-01-05 Max-Delbruck-Centrum Fur Molekulare Medizin Polypeptide variants of sleeping beauty transposase
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US11242375B2 (en) * 2015-09-04 2022-02-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
WO2017133175A1 (en) 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
CN109562126A (zh) 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
AU2018231190B2 (en) * 2017-03-08 2023-05-25 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
CN107033248B (zh) 2017-05-03 2020-02-18 重庆精准生物技术有限公司 识别癌胚抗原的嵌合抗原受体及其应用
EP3729081B1 (en) * 2017-12-21 2025-02-19 F. Hoffmann-La Roche AG Car-t cell assay for specificity test of novel antigen binding moieties
CN108219004A (zh) * 2018-02-08 2018-06-29 吉林省拓华生物科技有限公司 双特异嵌合抗原受体修饰的t细胞、其制备方法及用途
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US12331318B2 (en) * 2018-07-13 2025-06-17 Lothar Germeroth Non-immunogenic engineered tissue and methods of producing and using the same
CN109593726A (zh) 2018-12-26 2019-04-09 重庆精准生物技术有限公司 增强car-t细胞归巢到实体肿瘤组织能力的试剂及其应用
CN117843812A (zh) * 2020-05-22 2024-04-09 重庆精准生物技术有限公司 逆转肿瘤微环境的融合蛋白及其应用
US20240009310A1 (en) 2020-08-24 2024-01-11 Charité - Universitätsmedizin Berlin A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6

Similar Documents

Publication Publication Date Title
JP7755890B2 (ja) Car発現ベクター及びcar発現t細胞
US12624088B2 (en) Chimeric receptor comprising a ligand binding domain and an endodomain comprising a cytokine receptor endodomain and an intracellular T cell signalling domain
US20220002401A1 (en) Chimeric antigen receptor and its use
CN107207616B (zh) 抗cd70嵌合抗原受体
KR102226917B1 (ko) 신규 유전자 변형 자연살해 세포주 및 그의 용도
ES2905557T3 (es) Receptor de antígeno quimérico anti-CD30 y su uso
US20200239545A1 (en) Receptor
WO2010065818A1 (en) Chimeric immunoreceptor useful in treating human cancers
CA2629749A1 (en) Chimeric immunoreceptor useful in treating human cancers
ES2926227T3 (es) Receptor de antígeno quimérico con dominio de activación o bloqueo del receptor de citoquinas
AU2018231190A1 (en) Immune cell compositions and methods of use
WO2022037562A1 (en) Engineered immunoresponsive cells and uses thereof
CN114867490A (zh) 细胞因子调控表达的免疫效应细胞
JP2024531446A5 (cg-RX-API-DMAC7.html)
US20220325241A1 (en) Immune effector cell for co-expressing chemokine receptor
JP2023540022A5 (cg-RX-API-DMAC7.html)
CN120623314A (zh) 识别kras g12v抗原短肽的t细胞受体、复合物、药物组合物及用途
WO2021044439A1 (en) Inducible cytokine signals & methods for immunotherapy
WO2026096531A1 (en) Antigen-specific t cell compositions and methods of making the same
RU2024105406A (ru) Клетки, экспрессирующие il-10, для улучшенной иммунотерапии рака
AU2007237297B2 (en) Chimeric immunoreceptor useful in treating human cancers
WO2024011335A1 (zh) 经修饰的免疫细胞
CN120917054A (zh) 嵌合细胞因子受体,其包含截短的IL2Rβ和IL2Rγ